Artiva Biotherapeutics Inc (ARTV)
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company listed on Nasdaq under the ticker ARTV. The company is focused on developing natural killer, or NK, cell-based therapies for autoimmune diseases and cancer. Its lead candidate, AlloNK, is an off-the-shelf NK cell therapy being studied for conditions including rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, pemphigus vulgaris, ANCA-associated vasculitis subtypes, and B-cell non-Hodgkin lymphoma. Artiva is also advancing AB-201, an allogeneic CAR-NK program directed at HER2 for solid tumors such as breast, gastric, esophageal, and bladder cancers, as well as AB-205, an allogeneic CAR-NK candidate targeting CD5 for hematological malignancies. Founded in 2019, the company is headquartered in San Diego, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ARTV
|
$9.75
|
13.2% Upside
|
Fair
|
$35.80
|
315.8% Upside
|
Bargain
|
Fair
|
0.0%
|
November 18, 2026
|
1.2x
|
420.9 M
|
81.399 M
|
2.3%
|
40.0%
|
10.5
|
84.7%
|
